干燥综合征 B 细胞治疗中治疗驱动的外周血转录组重塑及 ESSDAI 与 STAR 应答的基线预测因子
Treatment-driven peripheral blood transcriptomic remodelling and baseline predictors of ESSDAI and STAR response to B-cell therapy in Sjögren's disease
干燥综合征（SjD）是一种自身免疫病。研究者对一项二期试验中 43 名活动性患者的全血 RNA 进行测序，比较利妥昔单抗（抗 CD20）、贝利尤单抗（抗 BlyS/BAFF）及两者序贯治疗与安慰剂。结果显示序贯治疗引起最大转录组变化。基线表达谱可预测两类疗效指标：ESSDAI 非应答者以补体调控、细胞毒和基质重塑通路为特征（曲线下面积 0.89）；STAR 非应答者则以 IL-1/IL-18/FcγR 为核心的髓系模块为特征（0.80），两者基因完全不重叠。作者认为这提示存在不依赖 B 细胞的顽固炎症环路，为联合治疗提供靶点。
为什么推荐给您：小样本二期试验的转录组二次分析，提出两种疗效指标对应不同非应答机制，属值得关注。
不需要生物学背景，多打比方
正在获取全文并生成讲解（拿不到全文就依据摘要），大约需要 30–60 秒…
已等待 0 秒
这篇还没有动画
动画会把研究的流程、作用机制和关键结果一步一步演示出来，每一步都标明出自原文哪里。制作大约需要 30–60 秒。
摘要Abstract
OBJECTIVE: To characterise whole-blood transcriptomic profiles in adults with active Sjögren's disease (SjD) treated with anti-CD20 or BlyS/BAFF inhibition, identify markers of clinical response, and define inflammatory pathways linked to non-response.
METHODS: Whole-blood RNA sequencing was performed at baseline and week-24 in participants (n=43) from a phase II GSK trial (NCT02631538) evaluating rituximab (RTX), belimumab (BEL), and sequential BEL-RTX versus placebo. Differential expression (DESeq2; fold change >1.5; unadjusted P<0.01) was integrated with pathway enrichment and ligand-receptor analyses (Metascape, GSEA, curated interaction databases). Clinical response was defined using ESSDAI and STAR; responder groups were compared using descriptive statistics, correlations, and logistic regression with ROC-based evaluation.
RESULTS: Sequential BEL-RTX induced the largest transcriptional shift from baseline to week-24. Baseline differential expression identified distinct ligand-receptor predictors for each response definition. ESSDAI non-response was associated with higher baseline TGFB2, C4A, CD8A, and lower C4BPA, defining complement-regulated, cytotoxic and stromal-remodelling pathways (AUC 0.89). In contrast, STAR non-responders showed higher baseline expression of SPP1, TLR4, IL1R1, IL18R1, IL1RAP, TREM1, and FCGR2A, forming an IL-1/IL-18/FcγR-centred myeloid module (AUC 0.80). No ligand-receptor genes overlapped between ESSDAI and STAR. ESSDAI genes clustered non-responders distinctly, whereas STAR genes showed weak separation with no cluster concordance between the two response definitions.
CONCLUSION: The distinct ESSDAI and STAR ligand-receptor signatures indicate different systemic biological drivers of non-response to B-cell therapies in SjD. Their complete non-overlap suggests entrenched B-cell-independent inflammatory circuits, highlighting complement regulation, TGFB2-mediated remodelling, IL-1/IL-18 signalling and FcγR activation as rational treatment pathways beyond B-cell-targeted therapies.